| Name | Title | Contact Details |
|---|
Smoothie King is a global health-focused smoothie company founded in 1973 in Kenner, Louisiana. It pioneered the smoothie sales concept and has grown to become a leading brand in the industry. The company was acquired in 2012 by Wan Kim, who expanded its reach and offerings. Smoothie King operates over 1,000 locations worldwide, with its headquarters in Dallas, Texas. The company offers a diverse menu of smoothies made from non-GMO fruits and vegetables, catering to various nutritional goals such as weight management, energy boosts, and muscle recovery. In addition to smoothies, some locations provide sports beverages, energy bars, snacks, and vitamin supplements. Smoothie Kings mission is to promote health and wellness by delivering high-quality, nutritious products while emphasizing ingredient transparency.
Prime Case LLC is a leading provider of lawsuit funding and lawsuit advances for those expecting a cash settlement resulting from a pending lawsuit, verdict or judgment. The need for our legal funding & settlement funding service arises from the fact that the legal process is often slow and many plaintiffs simply cannot afford to wait for a fair settlement due to financial pressures. Prime Case LLC works directly with attorneys and paralegals nationwide to provide their clients with immediate financial help. Our attorney-focused, the plaintiff funding process is the simple, fast, and cost-effective way to fund your clients. Here at Prime Case Funding, we want to save both you and your staff time to focus on getting your client the largest case settlement possible. Referring Your Clients to Prime Case Funding means: 1. Simple Application 2. Minimal Paperwork 3.No Case Interference 4. Consistent Funding Agreements 5. Quick Funding Turnaround 6. Low Funding Rates Prime Case LLC will limit funding to 10%-15% of the case value, to ensure your ability to settle the case will not be compromised. In our experience, plaintiff funding never affects attorney fees or the way your firm handles the case.
JELD-WEN is a leading global designer, manufacturer and distributor of high-performance interior and exterior doors, windows, and related building products serving the new construction and repair and remodeling sectors. Headquartered in Charlotte, N.C., the company operates facilities in 16 countries in North America and Europe and employs approximately 18,000 people. Since 1960, the JELD-WEN team has been committed to making quality products that create safe and sustainable environments for customers, associates and local communities. The JELD-WEN family of brands includes JELD-WEN® worldwide, LaCantina™ and VPI™ in North America, and Swedoor® and DANA® in Europe. For more information about JELD-WEN or to join our team, visit https://www.corporate.jeld-wen.com/.
Saltzman Enterprise Group (SEG) is all about helping Companies and Individuals reach their full potential. Every Company and Individual has the ability to achieve more and accelerate their growth. Saltzman Enterprise Groups assist their clients by providing the following services; Strategy, Thought Leadership, Coaching and Culture. To learn more about Saltzman Enterprise Group, visit www.saltzmanEG.com
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.